Senhwa Biosciences, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Senhwa Biosciences, Inc..The latest application filed is for "combination therapy of tetracyclic quinolone analogs for treating cancer".

Company Profile

7.14.16

Senhwa Biosciences, Inc. - New Taipei City TW
SENHWA BIOSCIENCES, INC. - New Taipei TW

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination Therapy Of Tetracyclic Quinolone Analogs For Treating Cancer App 20220088029 - SOONG; John	2022-03-24
Pharmaceutical Compositions Of Tetracyclic Quinolone Analogs And Their Salts App 20220062294 - LIU; Hshiou-ting ; et al.	2022-03-03
Combination therapy of tetracyclic quinolone analogs for treating cancer Grant 11,229,654 - Soong January 25, 2	2022-01-25
Combination therapy of tetracyclic quinolone analogs for treating cancer Grant 11,191,770 - Soong December 7, 2	2021-12-07
Antiviral Compounds And Method For Treating Rna Viral Infection, Particularly Covid-19 App 20210308110 - SOONG; TAI-SEN	2021-10-07
Antiviral Compounds And Method For Treating Hepatotropic Viral Infection, Particularly Hepatitis B And Hepatitis D App 20210308137 - SOONG; Tai-Sen	2021-10-07
Combination Therapy Of Tetracyclic Quinolone Analogs For Treating Cancer App 20210113584 - SOONG; John	2021-04-22
Crystalline Forms Of Quinoline Analogs And Salts Thereof, Compositions, And Their Methods For Use App 20210046082 - LIU; Hshiou-ting	2021-02-18
Tetracyclic Compounds And Their Salts, Compositions, And Methods For Their Use App 20210046071 - SOONG; John	2021-02-18
Combination therapy of tetracyclic quinolone analogs for treating cancer Grant 10,857,156 - Soong December 8, 2	2020-12-08
Combinations For Immune-modulation In Cancer Treatment App 20200123153 - SOONG; John	2020-04-23
Quinolone Analogs And Their Salts, Compositions, And Method For Their Use App 20190374550 - LIU; Hshiou-ting ; et al.	2019-12-12
Combination Therapy Of Tetracyclic Quinolone Analogs For Treating Cancer App 20190224209 - Soong; John	2019-07-25
Crystalline forms of quinolone analogs and their salts Grant 9,957,282 - Ryckman , et al. May 1, 2	2018-05-01
Crystalline Forms Of Quinolone Analogs And Their Salts App 20170166590 - Ryckman; David M. ; et al.	2017-06-15
Combination Therapy Of Tetracyclic Quinolone Analogs For Treating Cancer App 20170143737 - SOONG; John	2017-05-25
Pyrazolopyrimidines and related heterocycles as CK2 inhibitors Grant 9,303,033 - Haddach , et al. April 5, 2	2016-04-05
Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators Grant 9,062,043 - Chua , et al. June 23, 2	2015-06-23
Polymorphs and salts of a kinase inhibitor Grant 8,853,235 - Ryckman , et al. October 7, 2	2014-10-07
Quinolone analogs and methods related thereto Grant 8,853,234 - Nagasawa , et al. October 7, 2	2014-10-07
Pyrazolopyrimidines And Related Heterocycles As Ck2 Inhibitors App 20140094448 - Haddach; Mustapha ; et al.	2014-04-03
Pyrazolopyrimidines and related heterocycles as CK2 inhibitors Grant 8,575,177 - Haddach , et al. November 5, 2	2013-11-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.